LAGIPRA peptide
LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes.
For research use only. We do not sell to patients.
- Formula: C264H406N64O78S
- Molecular Weight:5756.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
LAGIPRA peptide (300 nmol/kg; sc; once a day for 14 days) shows a small (4% reduction) effect on body weight and transient reduction (during the first 24-48 hours) in food intake, decreases fasting glucose and insulin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male IR mice (onsisting of 60% fat, 20% carbohydrate, and 20% protein caloric content D12492; Research Diets)[1]
-
Dosage:300 nmol/kg
-
Administration:SC; once a day for 14 days
-
Result:Showed a small (4% reduction) effect on body weight and transient reduction (during the first 24-48 hours) in food intake, decreases fasting glucose and insulin.
Chemical Information
-
Molecular Weight 5756.50
-
Formula C264H406N64O78S
-
Synonyms
Long acting GIPRA-1
-
Sequence
Tyr-{Aib}-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-{Lys(AEEA-AEEA-γGlu-C20 diacid)}-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln
-
Sequence Shortening
Y-{Aib}-EGTFISDYSIAMDK-{Lys(AEEA-AEEA-γGlu-C20 diacid)}-HQQDFVNWLLAQKGKKNDWKHNITQ
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz